Recent Updates — EVFM

Evofem Biosciences entered into a fifth amendment to its Securities Purchase Agreement with Adjuvant Global Health Technology Fund. The amendment accelerates the maturity of the outstanding convertible promissory notes to the earlier of December 1, 2026, or a Change of Control event. Additionally, the company removed certain affirmative covenants from the agreement and restricted prepayment prior to the new maturity date without investor consent. Evofem Biosciences operates in the biotechnology sector, developing therapies for women's health.

Evofem Biosciences entered into a Manufacturing Agreement with Zhaoke to produce PHEXX, its hormone-free contraceptive vaginal gel. This second manufacturing source is expected to improve supply chain flexibility and reduce unit costs by 40% or more following regulatory approval. The company plans to submit a supplemental new drug application (sNDA) to the FDA in mid-2027 for PHEXX manufactured at this additional facility, with commercial sales anticipated upon approval. Evofem Biosciences is a pharmaceutical company commercializing FDA-approved sexual and reproductive health products including PHEXX and SOLOSEC.

Evofem Biosciences, Inc. entered into a promissory note with HUB Cyber Security, Ltd. on July 8, 2026, for an aggregate principal amount of $706,304. The subordinated note carries a 12% annual interest rate, compounded monthly, maturing in eleven months. The agreement includes a $2,000 weekly monitoring fee and a $14,126 administration fee, both payable at maturity. Evofem Biosciences, Inc. is a biotechnology company focused on women's health products and services.